February 13, 2024The LancetOpen Access

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

View Full Paper

Ask AI

Bookmark

Weekly abatacept significantly lowers the risk of progression to rheumatoid arthritis in symptomatic, autoantibody-positive individuals.
Only 6% on abatacept reached the primary endpoint during 12-month treatment versus 29% on placebo, with 25% versus 37% progressing by 24 months.
A randomised, double-blind, multicentre, parallel, placebo-controlled trial tested 125 mg subcutaneous abatacept against placebo in 213 adults.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized double-blind trial reports weekly abatacept reduces progression to rheumatoid arthritis in at-risk adults, indicating therapeutic intervention during the preclinical phase is feasible.

Cite This Study

Cope et al. (2024) studied this question.

synapsesocial.com/papers/68e7941db6db6435877059a0 https://doi.org/10.1016/s0140-6736(23)02649-1

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial reports weekly abatacept reduces progression to rheumatoid arthritis in at-risk adults, indicating therapeutic intervention during the preclinical phase is feasible.

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Key Points

Discussion

Implication

Cite This Study

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider